AdvanSource Biomaterials Corp. appointed a new interim CFO after the departure of Eric Walters, who resigned to pursue “other personal interests.”
The Wilmington polymer materials maker named David Volpe as interim CFO.
Walters, who joined AdvanSource in 2005 while it was still operating as CardioTech International Inc., led the company though the $7.5 million sale of its Gish Biomedical Inc. subsidiary in July 2007 and the March 2008 deal to sell its Catheter and Disposables Technology Inc. division for $1.2 million.
In May 2008, CardioTech announced plans to re-brand itself as AdvanSource, in order to focus on its polymers business.
The company’s CardioPass synthetic coronary bypass graft is in clinical trials at two sites in Europe.